Patients with cystic fibrosis who undergo invasive mechanical ventilation may have a lower risk for in-hospital mortality.
Bacterial load was a stable characteristic associated with worse quality of life and more airway inflammation in patients with bronchiectasis.
Final height was impaired in boys with cystic fibrosis who experienced a rapid increase in body mass index between the ages of 1 and 6.
The FDA has expanded the indication for Kalydeco to include treatment of cystic fibrosis in patients 6 months of age and older.
Approximately 70% azithromycin users with cystic fibrosis returned to ≥90% of baseline FEV1 compared with 61% of azithromycin nonusers.
Unselective small-molecule ion channels can restore host defenses in the airway epithelia of patients with cystic fibrosis.
Systemic antifibrinolytic therapy in adult patients with cystic fibrosis has been associated with a reduced rate of hospital admissions for hemoptysis.
Improvements in pancreatic function biomarkers, including increases in fecal elastase-1 and decreases in serum immunoreactive trypsinogen, were seen in patients treated with lumacaftor and ivacaftor.